ARQ 501 in Subjects With Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT). ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Key facts

Study ID

NCT00075933

Run by

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

People needed

80

Starts

2003-09-01

Expected to finish

2007-01-01

Last updated by the study team

2009-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
• ECOG performance status greater than or equal to 1
• Life expectancy greater than three months
• Acceptable pretreatment clinical laboratory results

You may not qualify if…

• Subjects who have had chemotherapy or radiotherapy within 4 weeks
• Subjects receiving any other investigational agents
• Subjects with known untreated brain metastases
• Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD")
• Subjects with uncontrolled intercurrent illnesses
• Pregnant women

Where it is running

• Dana Farber/Partners CancerCare Inc — Boston, Massachusetts, United States
• Mary Crowley Medical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.